3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Terminated
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Classical hematology
2
Gastrointestinal
1
Conditions
Venous Thrombosis
2
Venous Thromboembolism
2
Pulmonary Embolism
2
Gastrointestinal Neoplasms
1
Interventions
Dalteparin
11
apixaban
9
Enoxaparin
7
edoxaban
5
Tinzaparin
5
Rivaroxaban
4
Heparin, Low-Molecular-Weight
4
Dabigatran
3
bemiparin
2
abelacimab
2
Warfarin
2
Nadroparin
2
MAA868
2
Fondaparinux
2
reviparin
1
myotubularin
1
isoquercitrin
1
certoparin
1
atezolizumab
1
acarboxyprothrombin
1
Ultrasonography, Doppler, Duplex
1
Rosuvastatin Calcium
1
Phenprocoumon
1
Models, Biological
1
Medication Therapy Management
1
Intermittent Pneumatic Compression Devices
1
Imaging, Three-Dimensional
1
Hospitals
1
Heparin
1
Fluorodeoxyglucose F18
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Venous Thrombosis
×
abelacimab
×
Clear all
NCT05171075
2026-04-17
MAGNOLIA
Anthos Therapeutics, Inc.
Phase 3
Terminated
417 enrolled
NCT05171049
2026-02-23
ASTER
Anthos Therapeutics, Inc.
Phase 3
Terminated
1,150 enrolled